Suppr超能文献

磷脂酶C抑制剂:一类新型细胞毒性药物。

Phospholipase C inhibitors: a new class of cytotoxic agents.

作者信息

Perrella F W, Chen S F, Behrens D L, Kaltenbach R F, Seitz S P

机构信息

Cancer Research Group, DuPont Merck Pharmaceutical Company, Glenolden Laboratory, Pennsylvania 19036.

出版信息

J Med Chem. 1994 Jul 8;37(14):2232-7. doi: 10.1021/jm00040a016.

Abstract

A series of nitrocoumarin and nitrochromene derivatives have been prepared and shown to inhibit the phosphatidylinositol-specific phospholipase C(PLC)(IC50 < 10 micrograms/mL) isolated from human melanoma. The inhibition of PLC by nitrocoumarin 4a was time-dependent and irreversible. The inhibition of PLC was shown to interfere with inositide metabolism in whole cells (IC50 = 4 micrograms/mL) in a manner consistent with their proposed mode of activity. Finally, the compounds were shown to be growth inhibitory to cultured melanoma cells (ID50 = 2 micrograms/mL), suggesting that PLC may be an attractive new target for chemotherapeutic intervention.

摘要

已制备出一系列硝基香豆素和硝基色烯衍生物,它们能够抑制从人黑色素瘤中分离出的磷脂酰肌醇特异性磷脂酶C(PLC)(IC50 < 10微克/毫升)。硝基香豆素4a对PLC的抑制作用具有时间依赖性且不可逆。研究表明,对PLC的抑制会干扰全细胞中的肌醇磷脂代谢(IC50 = 4微克/毫升),其方式与所提出的活性模式一致。最后,这些化合物对培养的黑色素瘤细胞具有生长抑制作用(ID50 = 2微克/毫升),这表明PLC可能是化疗干预的一个有吸引力的新靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验